Research
Research Projects - Extramural
| S.N. | Title | Name of PI | Funding Agency | Starting Year | Ending Year |
|---|---|---|---|---|---|
|
1 |
Understanding arterial wall fibrosis in Takayasu arteritis roll of circulating T helper lymphocytes in driving the activation of TGF-Beta meditated pathways in aoristic adventitial fibroblast and its potential for therapeutic modulation adventitial fibroblast and its potential for therapeutic modulation |
Dr. Durga P Misra |
SERB |
2024 |
2026 |
|
2 |
Preclinical implication of liposomal hydrogel loaded dual drug metadoxin and PDE-5 in hibitor for transdermal delivery to target myofibroblast to ameliorat fibrosis |
Dr. Vikas Agarwal |
SERB |
2023 |
2026 |
|
3 |
Antinuclear antibody immunofluorescence patterns in systemic lupus erythematosus: Diagnostic and prognostic evaluation using artificial intelligence. |
Dr. Amita Aggarwal |
ICMR |
2023 |
2024 |
|
4 |
Anti cytokine antibodies in SLE: their prevelence, persistence over |
Dr. R. Chatterjee |
APLAR |
2023 |
2024 |
|
5 |
Magnitude, characteristics and endurance of Immune Response to COVID-19 Vaccination in patients with systemic Lupus Erythematosus a Multicentric Conhort Study |
Dr. Amita Aggarwal |
ICMR |
2023 |
2025 |
|
6 |
Evaluation of p-glycoprotein expression on lymphocytes from patients with inflammatory rheumatic diseases as a biomarker for treatment responsiveness to disease-modifying anti-rheumatic drugs |
Dr. Durga P Misra |
UPCST |
2023 |
2025 |
|
7 |
A Randomized Double Blind Pacebo Control Clinical Study to Evaluate the Immunomodulatory Effect of Swarnprashan in Moderately Malnourished Children |
Dr. Vikas Agarwal |
CCRAS, New Delhi |
2023 |
2026 |
|
8 |
Evaluation of HMGB-1-TLR4/RAGE-TAK-1 pathway in induction of cells in SLE nephritis |
Dr. Vikas Agarwal |
ICMR |
2023 |
2026 |
|
9 |
Preclinical disease in sib ling of patients with enthesitis-related arthritis: clinical immunological and gut flora evaluation |
Dr. Amita Aggarwal |
ICMR |
2023 |
2026 |
|
10 |
Influcence oh HLA B27 on monocyte/macrophages in patients with enthesitis related arthritis category of Juvenile idiopathic arthritis |
Dr. Amita Aggarwal |
ICMR |
2023 |
2025 |
|
11 |
Dural drug (phosphodiesterase 5 inhibitor and tankyrase inhibitor) loaded ultra flexible nanoliposome selective targeting myofibroblast to ameliorate fibrosis in systemic sclerosis mouse model |
Dr. Anurag K Srivastava Dr. Vikas Agarwal |
ICMR |
2022 |
2025 |
|
12 |
Evaluation of microparicle proteins in post Covid-19 lung fibrosis |
Dr. Durgesh Dubey Dr. Vikas Agarwal |
DHR, ICMR |
2021 |
2024 |
|
13 |
Evaluation of D2R pathway for potential anti-viral therapy in Japanese Encephalitis Virus |
Dr. Sukanya Tripathy Dr. Vikas Agarwal |
ICMR |
2021 |
2024 |
|
14 |
Evaluation of peripheral blood T and B cell responses to M tuberculosis membrane and the asociated antigen alpha crystallin as progression biomarkers for tuberculosis |
Dr. A. Aggarwal |
ICMR |
2020 |
2023 |
|
15 |
Study on Polio and Non-Polio enterovirus infections in children with immunodeficiency at multiple medical institutes across India |
Dr. A. Aggarwal |
WHO/NIV |
2020 |
2023 |
|
16 |
Validation of the myositis specific antibody profiles in an Indian Cohort of patients with inflammatory myositis using immunoprecipitation assay- BirdBath Foundation |
Dr. Latika Gupta |
Bird Bath Foundation |
2020 |
2022 |
|
17 |
A multi-center, randomized controlled phase III study to evaluate the clinical outcomes and safety of tocilizumab along with standard of care in patients with cytokine release syndrome associated with COVID-19 infection |
Dr. V. Agarwal |
JSS Medcical Res India Pv. Ltd. |
2020 |
2022 |
|
18 |
Evaluation of cGMP/PKG pathway in pathways in Idiopathic Pulmonary Fibrosis: an in vitro and in vivo study” |
Dr. Mohit Kumr Rai Dr. Vikas Agarwal |
DHR, ICMR |
2020 |
2023 |
|
19 |
Understanding pathogenesis of Takayasu arteritis-transcriptiomics applied to peripheral blood mononuclear cells (PBMC) and involved vessels and the role of various T-cell subsets |
Dr. D.P. Misra |
ICMR |
2019 |
2022 |
|
20 |
Disease outcome in adulthood of children with enthesitis related arthritis (ERA) category of Juvenile Idiopathic arthritis and its predictors: a cohort study |
Dr. A. Aggarwal |
ICMR |
2019 |
2022 |
|
21 |
Il-36 role is enthesitis related arthritis |
Dr. S. Majumdar |
DST |
2019 |
2021 |
|
22 |
Multi-institutional network program on systemic lupus erythematous understanding the diversity of SLE |
Dr. A. Aggarwal |
DBT |
2018 |
2023 |
|
23 |
FPID_SGPGI primary immunodeficiency centre |
Dr. A. Aggarwal |
FPID |
2018 |
2023 |
|
24 |
Exploration of methylamine as a novel metabolite driving endothelial cell apoptosis and fibrosis in scleroderma |
Dr. D.P. Misra |
APLAR |
2018 |
2020 |
|
25 |
Evaluation of circulating endothelial and platelet microparticles in scleroderma and their relationship with subclinical atherosclerosis in Indian patients. |
Dr. D.P. Misra |
IRA |
2017 |
2019 |
|
26 |
Translating role of Class-I HDACs in Steroid Resistance in Childhood Nephrotic Syndrome |
Dr. V. Agarwal |
UPCST, Lko |
2017 |
2019 |
|
27 |
Endogenous Toll like receptor ligands in pathogenesis of adult and juvenile spondyloarthropathy |
Dr. A. Aggarwal |
DST |
2016 |
1019 |
|
28 |
Idenfification of biomarkers for infection-induced reactive arthritis based on the inflammation amplifier (India-Japan) |
Dr. R.N. Misra |
DST |
2015 |
2018 |
|
29 |
Federation of Primary Immunodeficiency: FPD_SGPGI Diagnostic Center for Primary Immunodeficiency |
Dr. A. Aggarwal |
USA |
2013 |
2018 |
|
30 |
Identification of immunodominant epitopes of HLA B*2705 binding salmonella typhimurium outer membrane proteins (OMP) A and D in patients with reactive arthritis and Undifferentiated spondyloarthropathy |
Dr. R.N.Misra |
DBT |
2013 |
2016 |
|
31 |
Gut microbiome: Role in pathogenesis of ERA-JIA |
Dr. A. Aggarwal |
DBT |
2012 |
2015 |
|
32 |
Role of innate immune cells in pathogenesis of juvenile idiopathic arthritis - enthesitis related arthritis" |
Dr. A. Aggarwal |
ICMR |
2012 |
2015 |
|
33 |
FIST Program 2011 |
Departmental |
DST |
2011 |
2016 |
|
34 |
Role of micro RNA involved in immune regulation in Enthesitis related arthritis form of Juvenile arthritis |
Dr. A. Aggarwal |
DBT |
2011 |
2014 |
|
35 |
Identification of Urinary biomarkers for diagnosis, prognosis and follow-up of patients with SLE nephritis |
Dr. A. Aggarwal |
DBT |
2011 |
2014 |
|
36 |
Validation of indigenous anti-TTG kit |
Dr. A. Aggarwal |
DBT |
2011 |
2012 |
|
37 |
Role of TLR in pathogenesis of JIA |
Dr. A. Aggarwal |
ICMR |
2008 |
2012 |
|
38 |
Immune mechanisms in enthesistis related arthritis: gene expression approach |
Dr. A. Aggarwal |
DBT |
2008 |
2012 |
|
39 |
Invitro inhibition of T cell cytokine production by methotrexate: Can it predict response to MTX in patients with RA |
Dr. A. Aggarwal |
DST |
2008 |
2011 |
|
40 |
Serological testing for Hepatitis B markers in samples from Bhutan |
Dr. S. Naik |
WHO |
2007 |
2007 |
|
41 |
Innate immune responses and macrophage biology in Leishmania donovani infection |
Dr. S Naik/ Dr. A. Aggarwal |
DRDO |
2007 |
2010 |
|
42 |
Establishment of Bioinformatics Infrastructure Facility (BIF) for the promotion of Biology Teaching through Bio-Informatics (BTBI) |
Dr. S. Naik |
DBT |
2006 |
2007 |
|
43 |
Bio-medical informatics centre |
Dr. S. Naik |
ICMR |
2006 |
2009 |
|
44 |
Cellular Immune Responses to Hepatitis E Virus (HEV) infection |
Dr. S. Naik |
DBT |
2006 |
2009 |
|
45 |
Genotyping of non-HLA genes for severity and susceptibility to rheumatoid arthritis |
Dr. Deepali Gambhir |
DST |
2005 |
2008 |
|
46 |
Mechanisms of nucleosome clearance in Systemic Lupus Erythematosus: Correlation with disease activity |
Prof. R. Misra |
ICMR |
2005 |
2008 |
|
47 |
Immunopathogenesis of cartilage and bone destruction in juvenile idiopathic arthritis |
Dr. A. Aggarwal |
ICMR |
2005 |
2008 |
|
48 |
Pheotypic and functional charocterization of T cells in synovial fluid of children with Juvenile arthritis |
Dr. A. Aggarwal |
DST |
2004 |
2007 |
|
49 |
Etiology of cirrhosis in Uttar Pradesh & the role of molecular variants of hepatitis B virus causing cirrhoisis. |
Dr. S. Naik |
UPCST |
2003 |
2006 |
|
50 |
Molecular mechanisms of action of disease modifying anti-rheumatic drugs on synoviocytes |
Dr. S. Naik |
DST |
2003 |
2006 |
|
51 |
Role of bacteria in pathogensis of Juvenile ideopathic arthritis |
Dr. A. Aggarwal |
ICMR |
2002 |
2005 |
|
52 |
FIST Program 2002. |
Immunology |
DST |
2002 |
2007 |
|
53 |
Multi Institutional Programme for Identification of Novel leads from Traditional Medicinal Plants Through Molecular Drug Targets |
Dr.V.K.Singh |
DBT |
2001 |
2003 |
|
54 |
Core sets of outcome measures for disease activity and disease damage assessment, and definition of improvement for Juvenile Systemic Lupus Erythmatosus and Juvenile Dermatomyositis. |
Dr. A. Aggarwal |
NIH/EU |
2001 |
2003 |
|
55 |
Anti-Endothelial cell Antibodies (AECA) in Takayasu's Arteritis (TA): Antigenic Targets, Pathogenicity and Specificity |
Dr. S. Nityanand |
UPCST |
2001 |
2003 |
|
56 |
Characterization and pathogenetic potential of synovial fluid immune complexes in juvenile rhemumatoid artaritis |
Dr.Amita Aggarwal |
UPCST |
2000 |
2002 |
|
57 |
Identification of Immunoprophylactic Agents for Visceral Leishmaniasis based on TH1 Stimulatory Proteins |
Dr. S. Naik |
DBT |
2000 |
2003 |
|
58 |
Immunomodulators from Indian Medicinal plants |
Dr. V.K. Singh |
CSIR |
2000 |
2003 |
|
59 |
Evaluation of thymopentin analogs as immunomodulator |
Dr. V.K. Singh |
UPCST |
1999 |
2001 |
|
60 |
Immunological basis of aplastic anemia |
Dr. S. Nityanand |
INSA |
1998 |
2001 |
|
61 |
Study with human retinal S-antigen epitope mapping in uveitis patients |
Dr. V.K. Singh |
ICMR |
1998 |
1999 |
|
62 |
Studies on Pathogenesis of chronic liver disease in chronic hepatitis B virus infection |
Dr. S. Naik |
DST |
1998 |
2001 |
|
63 |
Immunopathogenetics mechanism in patients with undifferentiated spondyloarthropathy |
Prof. R.N.Misra |
DST |
1998 |
2002 |
|
64 |
A study of myositis-specific autoantibodies in patients with idiopathic inflammatory myopathies and their correlation with clinical epidemiological and immunogenetic characteristics. |
Dr. R.N.Misra |
DBT |
1997 |
1999 |
|
65 |
Specificity of response to retinal antigens in ocular diseases |
Dr. V.K. Singh |
UPCST |
1996 |
1998 |
|
66 |
Study of alterations in proinflammatory cytomines in systemic onset & polyarticular onset types of juvenile rheumatoid arthritis. |
Dr. A. Aggarwal |
DST |
1996 |
1998 |
|
67 |
Molecular epidemiology of hepatitis B virus infection. |
Dr. S. Naik |
DBT |
1996 |
1999 |
|
68 |
Anthropological analysis of Indian population by oligonucleotide typing of HLA class-II genes: A multicentric study. |
Dr. S. Naik |
DBT |
1996 |
1999 |
|
69 |
Molecular and functional consequences of hepatitis B Virus infection of immune cells |
Dr. S. Naik |
DAE |
1996 |
1999 |
|
70 |
The role of cytoykines in low response to nepatitis B vaccine in chronic renal failure patients. |
Dr. S. Naik |
ICMR |
1994 |
1996 |
|
71 |
Correlation of in vitro immunological response to disease modifying immunology anti rheumatic druges with in vivo therapeutic response in rheumatoid arthritis. |
Dr. S. Naik |
CSIR |
1994 |
1997 |
|
72 |
Role of peptide M Uveitopathogenic fragmant of 45 Kda retinal S-antigen in human Uveitis. |
Dr. V.K. Singh |
ICMR |
1992 |
1995 |
|
73 |
Effect of elevated temperatures on cytotoxic functions |
Dr.V.K. Singh |
DST |
1992 |
1995 |
|
74 |
Role of protein C in pathogenesis of thrombosis in systemic lupus erythematosis and recrurrant abortions. |
Dr. A. Parashar |
ICMR |
1990 |
1992 |
|
75 |
Role of mycobacterial antigens in the pathogenesis of rheumatoid arthritis |
Dr. S. Naik |
ICMR |
1990 |
1992 |
Intramural Projects
| S.N. | Title | Name of PI | Funding Agency | Starting Year | Ending Year |
|---|---|---|---|---|---|
|
1 |
In vitro evaluation of the cross talk between T lymphocytes and macrophages in Takavasu arteritis and its potential theraputic modulation |
Dr. D.P. Misra |
SGPGI |
2024 |
2025 |
|
2 |
Evaluation of the in vitro effectiveness of a combination of immunosuppressive with antifibrotic therapy on T lymphocyte activation in Takayas arteritis |
Dr. D.P. Misra |
SGPGI |
2024 |
2025 |
|
3 |
Tofacitinib in enthesitis related arthritis category of juvenile idiopathic arthritis (JIA-ERA): Impact on pro-inflammatory mediators |
Dr. A. Aggarwal |
SGPGI |
2023 |
2024 |
|
4 |
Paeumococcal vaccination in SLE: comparsion of single dose versus sequential vaccine Immunogenicity and impact on disease |
Dr. A. Aggarwal |
SGPGI |
2022 |
2024 |
|
5 |
Evaluations of TFG-B Induced Canonical and Non Canonical Fibrotic Pathways in Fibroblasts Derived from stricture esophagu |
Dr. V. Agarwal |
SGPGI |
2020 |
2022 |
|
6 |
Characterization of circulating microparticles in ANCA vasculitis and their role in inducing endothelial injury and glomerulonephritis |
Dr. D.P. Misra |
SGPGI |
2020 |
2023 |
|
7 |
To evaluate the role of CXCR2 Ligands (IL-8 and Gro-a) on A1K1 and A1K5 Imbalance in chgondrocytes Derived form OA cartilage |
Dr. V. Agarwal |
SGPGI |
2019 |
2021 |
|
8 |
Outcome in Adulthood of children with enthesitis related arthritis (ERA) category of juvenile idiopathic arthritis (JIA) and its predictors |
Dr. A. Aggarwal |
SGPGI |
2019 |
2021 |
|
9 |
Determination of Myositis specific and Myositis Associated antibody profiles of Indian Myositis patients using the Immunoprecipitation assay |
Dr. Vikas Agarwal |
SGPGI |
2019 |
2022 |
|
10 |
Prediction of Response to Methotrexate in rheumatoid arthritis: Using Genes involved in Adenosine pathway |
Dr. A. Aggarwal |
SGPGI |
2018 |
2020 |
|
11 |
MRI as determinant of outcomes in inception cohort of reactive arthritis |
Dr. Latika Gupta |
SGPGI |
2018 |
2020 |
|
12 |
Do serum and urinary C3d and C4d level reflect disease activity in patient with lupus nephritis |
Dr. R.N. Misra |
SGPGI |
2018 |
2019 |
|
13 |
Validation of Rat Excision Wound Model and Exploring the Role of compound X in wound Healing |
Dr. D.P. Misra |
SGPGI |
2017 |
2019 |
|
14 |
Evaluation of Clincial and Serologic Parameters Predisposing to Subelinical is Spondyloarthropathy |
Dr. D.P. Misra |
SGPGI |
2017 |
2019 |
|
15 |
Evaluation of anti-fibrotic role of inhibitors of 5HT2 (Terguride) and 5 HT2B (SB204741) on fibroblast isolated from omentum and peritoneum of patients on continuous ambulatory peritoneal dialysis |
Dr. V. Agarwal |
SGPGI |
2017 |
2019 |
|
16 |
Clinical and radiological study of foot involvement in rheumatoid arthritis |
Dr. V. Agarwal |
SGPGI |
2017 |
2019 |
|
17 |
Role of IL-22 in enthesitis related arthritis (ERA) category of juvenile idiopathic arthritis (JIA). |
Dr. A. Aggarwal |
SGPGI |
2016 |
2018 |
|
18 |
Evaluation of immune response to alpha crsyatallinantigen Mycobacterium tuberculosis as a predictor of progressive TB infection in patients with autoimmune disorders |
Dr. RN Misra |
SGPGI |
2016 |
2018 |
|
19 |
CD39 positive 1 regulatory cells in rheumatoid arthritis as markar of MTX response. |
Dr. A. Aggarwal |
SGPGI |
2015 |
2017 |
|
20 |
Association of TNFAIP3, TNFSFS and ITGAM polymorphism with SLE in North Indian Population. |
Dr. R.N. Mishra |
SGPGI |
2015 |
2017 |
|
21 |
To explore the effect of PDE5 inhibitor on TGFβ mediated canonical and non-canonical pathay in Fibroblast derived from scleroderma patient |
Dr. V. Agarwal |
SGPGI |
2014 |
2016 |
|
22 |
Can baseline MRP8/14 serve as a marker of MTX response in Rheumatoid arthritis? |
Dr. A. Aggarwal |
SGPGI |
2014 |
2016 |
|
23 |
Autoantibody profile (Myositis Specific and Associated autoantibody in North Indian patients with Idiopathic inflammatory Myositis and clinical correlation |
Dr. R.N. Mishra |
SGPGI |
2013 |
2015 |
|
24 |
MRP8/14 a TLR4 ligand in JIA_ERA and its association with disease activity |
Dr. A. Aggarwal |
SGPGI |
2012 |
2014 |
|
25 |
Effect of induction treatment on Double negative T cells , Th17 and T regulatory cells in lupus nephritis |
Dr. R.N. Mishra |
SGPGI |
2012 |
2014 |
|
26 |
Association of Plasma Neurotrophins in rheumatoid arthritis related secondary Fibromyalgia: a cross sectional and longitudinal study |
Dr. Able Lawrence |
SGPGI |
2012 |
2013 |
|
27 |
MDR-1 expression, function and polymorphism in systemic lupus erythematosus |
Dr. V. Agarwal |
SGPGI |
2011 |
2013 |
|
28 |
Expression funciton and polymorphism of MDR-1 in systemic lupus erythematosus and its correlation with response to glucocorticoids |
Dr. V. Agarwal |
SGPGI |
2011 |
2013 |
|
29 |
Evaluation of T regulatory cells, TH1 and TH2 cells in steroid sensitive vs steroid refractory nephrotic syndrome |
Dr. V. Agarwal |
SGPGI |
2011 |
2013 |
|
30 |
Study of serologic markers (ANCA, ASCA, anti glycan antibodies) in patients with ulcerative colitis and Crohu's disease |
Dr. V. Agarwal |
SGPGI |
2009 |
2011 |
|
31 |
Efficacy of Tadalafil in Secondary Raynaud’s Phenomenon Resistant to Vasodilator Therapy: A Double Blind Randomized Cross over Trial. |
Dr. V. Agarwal |
SGPGI |
2009 |
2011 |
|
32 |
Role of MDR in MTX non-responsiveness in rheumatoid arthritis |
Dr. V. Agarwal |
SGPGI |
2008 |
2010 |
|
33 |
MDR polymorphism in steroid responsive vs steroid refractory nephritic syndrome |
Dr. V. Agarwal |
SGPGI |
2008 |
2009 |
|
34 |
IL-1 gene cluster polymorphism in patients with enthesitis related arthritis (ERA) form of JIA |
Dr. A. Aggarwal |
SGPGI |
2008 |
2010 |
|
35 |
Effect of single nucleotide polymorphisms in human enterleukin-10 (IL-10) gene promoter region on the ex-vivo production of IL-10 in whole blood cultures from normal ethnic Indian volunteers |
Dr. Able Lawrence |
SGPGI |
2007 |
2008 |
|
36 |
In-vitro effect of Imatinib Mesylate on the proliferattion & synthesis of Extra cellular matrix by scleroderma fibro blasts |
Dr. Able Lawrence |
SGPGI |
2005 |
2006 |
|
37 |
Expression of multidrug registance proteins in Rheumatoid arthritis |
Dr. V. Agarwal |
SGPGI |
2005 |
2006 |
|
38 |
Can in vitro inhibition of cytokines predict response to methotrexate |
Dr. A. Aggarwal |
SGPGI |
2004 |
2006 |
|
39 |
Effect of sTNF-receptor therapy on mediators of angiogenesis and tissue destruction in patients with rheumatoid arthritis |
Dr. A. Aggarwal |
SGPGI |
2001 |
2002 |
|
40 |
Cloning and expression of bcr-abl fusion gene (Partial) in Escherichia coli. |
Dr. S. Dabadghao |
SGPGI |
2001 |
2002 |
|
41 |
Study of drug sensitivity in-vitro and multi drug resistance (MDR) gene expression in acute lymphatic leumaemia. Correlation with age and presence of philadelphia chromosome |
Dr. S. Dabadghao |
SGPGI |
2000 |
2001 |
|
42 |
Immunonistochemic localization and serological detection of basic fibroblast growth factor in patients with systemic sclerosis |
Dr. A. Aggarwal |
SGPGI |
2000 |
2001 |
|
43 |
Identification of Immunodominant antigen of salmonella Typhimurium in Salmonella Induced Reactive Arthritis |
Dr. R.N. Mishra |
SGPGI |
2000 |
2001 |
|
44 |
Expression of opioid receptors (s,u and k) in lymphoblastoid cell line (jurkat) |
Dr.V.K.Singh |
SGPGI |
2000 |
2001 |
|
45 |
Does the local milieu influence apoptosis of polymorphonuclear cells in synovial space of rheumatoid joints? |
Prof. Sita Naik |
SGPGI |
2000 |
2001 |
|
46 |
A study of the mechanism of induction of apoptosis by anti lymphocyte globulins (ALG) |
Dr. S. Nityanand |
SGPGI |
2000 |
2001 |
|
47 |
Generation of ScFV antibody for tumor targetting and imaging |
Dr. Aruna Parashar |
DBT |
1999 |
- |
|
48 |
Effect of high risk BFM protocol on tumour load in philadelphia chromosome positive cases of actue lymphatic leukeamia |
Dr. S. Dabadghao |
SGPGI |
1999 |
2000 |
|
49 |
Does antilymphocyte globulin act by inducing apoptosis of lymphocyte in aplastic anemia |
Dr. S. Nityanand |
SGPGI |
1999 |
2000 |
|
50 |
TH1 and TH2 cytokine profile of different groups of immunomodulators |
Dr.V.K.Singh |
SGPGI |
1998 |
1999 |
|
51 |
Role of proteases in surface expression of antigen in leukemia |
Dr.Aruna Parashar |
SGPGI |
1998 |
1999 |
|
52 |
Measurement of cyclophilin NFAT/NFKb/OCT nuclear factors & cyclosporine in chronicrenal failure patients |
Dr. Aruna Parashar |
SGPGI |
1998 |
1999 |
|
53 |
Characterization of opioid receptor for immunostimulatomy analogs of met-enkephalin |
Dr.V.K.Singh |
SGPGI |
1998 |
1999 |
|
54 |
Antibodies to keratin and perinuclear factor in patients with juvenile rheumatoid arthritis prevalence and antigenic targets |
Dr. A. Aggarwal |
SGPGI |
1998 |
1999 |
|
55 |
Methotrxate in Juvenile Rheumatoid arthritis : does it act by inhibition of IL-6 and TNF-alpha |
Dr. A. Aggarwal |
SGPGI |
1997 |
1998 |
|
56 |
Characterisation of antibodies to endothelial cell of different origins |
Dr. S. Nityanand |
SGPGI |
1997 |
1998 |
|
57 |
The role of complement activation in juvenile chronic arthritis |
Dr. A. Aggarwal |
SGPGI |
1996 |
1997 |
|
58 |
Evaluation of urinary excretion of complement degradation prolduct C3d relation to disease activity in systemic Lupus Erythematoisis |
Dr. R.N. Mishra |
SGPGI |
1995 |
1996 |
|
59 |
Role of nucleotides in signal transduction in leukemic cell |
Dr. A. Parashar |
SGPGI |
1994 |
1995 |
|
60 |
Role of calcium sensing receptor in uraemia chronic renal failure/osteoporosis osteodystrophy |
Dr. Aruna Parashar |
Self |
1994 |
1997 |
|
61 |
Prevalence & antigenic determinants of autoantibodies to endothelial cells |
Dr. S. Nityanand |
SGPGI |
1994 |
1995 |
|
62 |
Effect and specificity of Th1 & Th2 cell drived cytokine on T cell properative response in human patients |
Dr. V.K. Singh |
SGPGI |
1994 |
1995 |
|
63 |
Role of autoantibodies in delination of subset in juvenile arthritis |
Dr. R.N. Mishra |
SGPGI |
1993 |
1994 |
|
64 |
Mapping of the T cell stimulatory epitopes in different clinical types of tuberculosis |
Prof. Sita Naik |
SGPGI |
1993 |
1994 |
|
65 |
Investigations on T cell derived soluble suppressor facter in HBsAg carriers |
Prof. Sita Naik |
SGPGI |
1993 |
1994 |
|
66 |
Role of protein 'C' in thrombosis, SLE and recurout abortion |
Dr. Aruna Parashar |
SGPGI |
1992 |
1992 |
|
67 |
Immune response to klebsialla pneumoniae in patients with ankylesing spondylities & its modulation by sulphasalzine. |
Dr. R.N. Mishra |
SGPGI |
1992 |
1993 |
|
68 |
Role of quanine nucleotides in signal transduction in Leukemias |
Dr. Aruna Parashar |
SGPGI |
1991 |
1992 |
|
69 |
Suppression of experimental autoimmune uveitis by the administration of retinal S-antigen fragment |
Dr. V.K. Singh |
SGPGI |
1990 |
1991 |
|
70 |
Role of retinal S-antigen in human uveitis |
Dr. V.K. Singh |
SGPGI |
1990 |
1991 |
|
71 |
Profile of Anti-cadiolipin antibodies in connective tissue diseases and chronic infectinos diseases |
Dr. R.N. Misra |
SGPGI |
1990 |
1991 |
|
72 |
Mechanism of unresponsiveness to HbSAg in haemodialysis patients |
Prof. Sita Naik |
SGPGI |
1990 |
1991 |
|
73 |
Heat shock protein in RA |
Dr.Sita Naik |
ICMR |
1990 |
1992 |
|
74 |
Differences in immune status of asymptomatic & chronic liver disease KBV carriers & non responders to hepatitis B vaccine |
Dr. Sita Naik |
SGPGI |
1990 |
1991 |
|
75 |
Analysis of autoantibodies to nuclear antigens by immunoblotting |
Dr. R.N. Misra |
SGPGI |
1990 |
1991 |
|
76 |
Role of colonic mucins & colonic ecosystems in amoabic Infections |
Dr. A. Parashar |
SGPGI |
1989 |
1989 |
|
77 |
Evaluation of ANA test in routine samples and autoimmune diseases |
Dr.R.R.Singh |
SGPGI |
1989 |
1990 |
|
78 |
Difinition of clinical subsets of connective tissue diseases their antihudiear antibody profile |
Dr. R.R. Singh |
SGPGI |
1989 |
1990 |
|
79 |
Comparitive evaluation of CT Scan versus ELISA in cysticerous Ag Ab & tuberculous Ag/Ab in ring enhansing lesion of brain |
Dr. Aruna Parashar |
SGPGI |
1989 |
1990 |
|
80 |
Role of clonic mucin of enteric flora in amoebic pathogenecity |
Dr. Aruna Parashar |
SGPGI |
1988 |
1989 |
Drug Trail
| S.N. | Title | Name of PI | Funding Agency | Starting Year | Ending Year |
|---|---|---|---|---|---|
|
1 |
Protocol I4V-MC-JADX: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs with Moderately to Severely Active Rheumatoid Arthritis funded by Ali Lily |
Dr. Able Lawrence |
Eli Lily, USA |
2014 |
2015 |
|
2 |
Protocol 14V-MC-JADZ: A Randomized, Double-Blind, Active- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment with Disease- Modifying Antirheumatic Drugs funded by Ali Lily |
Dr. Able Lawrence |
Eli Lily, USA |
2014 |
2015 |
|
3 |
(A) OSKIRA-A phase III, multi-centre randomised, double-blind, placebo-controlled, parallel group study of two dosing regimens of Fostamatnib disodium in rheumatoid arthritis patients with an inadequate response to DMARDS's" (B)-OSKIRA-X: Along term extension study of assess the safety and efficacy of Fiostamatibib disodium in the treatemnt of rheumatoid arthritis" |
Dr. Able Lawrence |
Astra Zeneca AB, Sweden |
2011 |
2013 |
|
4 |
A Randomized, double blind, multicentric, placebo controlled, phase-II study assessing the safety and efficacy of intraarticular ex-vivo cultured adult allergenic mesenchymal stem cells in patients with Osteoarthritis (OA) of knee |
Dr. Vikas Agarwal |
Manipal Acunova Ltd., bangalore |
2011 |
2014 |
|
5 |
"A Phase Iib, 12 week Randomized, double Blind, Parallel Group, Placebo-Con trolled study to evaluate efficacy, safety and tolerability of 2,4 and 6 mg or Revamilast in patients with active Rheumatoid Arthritis who have had an inadequate response to Methotrexate" |
Dr. Vikas Agarwal |
Kendle, Ahmedabad |
2010 |
2012 |
|
6 |
"A Phase 3, randomized double blind placebo-controlled, multicentre study of the efficacy and safety of four 12-week treatemtn cycles (48 week) of epratuzumab in systemic lupus erythematous subjects with moderate to severe disease (EMBODY1) SL 0009 |
Dr. Vikas Agarwal |
Embody Bangalore |
2010 |
2012 |
|
7 |
A-15: A phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to compare the efficacy and safety of abatacept administered subcutaneously and Intravenously in subjects with rheumatoid arthtitis, receiving background methotrexate and experiencing an inadequate response to methotrexate |
Dr. A. Aggarwal |
BMS, Mumbai |
2008 |
2013 |
|
8 |
Drug Trial: A0081100 A 14-week, randomized, double-blind, placebo-controlled trial of pregabalin twice daily in patients with fibromyalgia |
Prof. RN Mishra |
Pfizer Pvt. Ltd. |
2007 |
2010 |
|
9 |
Drug Trial: A0081101: A 12-week, open label, safety trial of pregabalin in patients with fibromyalgia |
Prof. RN Mishra |
Pfizer Pvt. Ltd. |
2007 |
2010 |
|
10 |
A-06 A randomized, phase 3, controlled, double-blind, parallel-group, multicentre study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX along, in methotrexate native patients with active rheumatoid arthritis |
Dr Vikas Agarwal |
Roche Pvt. Ltd. |
2006 |
2011 |
|
11 |
A Multicenter, Randomized, Double-blind, Placebo controlled trial of Golimumab, a fully human anti-TNFa Monoclonal antibody, administered subcutaneously, in methotrexate-native subjects with active rheumatoid arthritis |
Prof. RN Mishra |
Centrocor Pvt. Ltd. |
2006 |
2012 |
|
12 |
Open-Label Evaluation of the efficacy and safety of etanercept in common rheumatology usage (ECRU). |
Prof. R. Mishra |
Wyeth Lederle Ltd. Mumbai |
2001 |
2002 |
|
13 |
Evalution of the efficacy and safety of leflunomide (HWA 486) in patients with active rheumatoid arthritis-multicenter study |
Prof. RN Mishra |
Hoecst Marion Roussel Ltd |
2000 |
2002 |
DM student projects funded by Indian Rheumatology Association
| S.N. | Title | Name of the Student | Name of Guide | Year(Start) | End(year) |
|---|---|---|---|---|---|
| 1 | Pneumococcal vaccination in SLE: Review of evidence, estimation of immunogenicity and cost-effectiveness analysis | Dr. Rudrarpan Chaterjee | Dr. Amita Aggarwal | 2020 | 2022 |
| 2 | Anti CD74 antibodies in JIA-ERA subgroup of patients | Dr. Anu Balakrishnan | Dr. Amita Aggarwal | 2020 | 2021 |
| 3 | Novel Th17 lymphocyte populations Th17.1 and PD1+th17 are increased in Takayasu arteritis and both Th17 and Th17.1 associate with active disease | Dr. Upendra Rathore | Dr. Durga P Misra | 2019 | 2022 |
| 4 | MIF and igA CD74 antibodies in Indian patients with ERA category of JIA | Dr. Anu Balakrishnan | Dr. Amita Aggawal | 2019 | 2022 |
| 5 | Etiology of raised serum creatinine in patients with systemic lupus erythematosus at presentation and association of number of crescents in renal biopsy with rapidly progressive renal failure | Dr. Rajat Kharbanda | Dr. Able Lawrence | 2019 | 2022 |
| 5 | Poor maternal and foetal outcomes in women with systemic sclerosis: an interview-based study at a tertiary centre. | Dr. Rajat Kharbanda | Dr. Vikas Agarwa | 2019 | 2022 |
| 6 | Poor maternal and foetal outcomes in women with systemic sclerosis: an interview-based study at a tertiary centre. | Dr. Rajat Kharbanda | Dr. Vikas Agarwal | 2019 | 2022 |
| 7 | Pneumococcal vaccination in systemic lupus erythematosus: review of evidence, estimation of imunogenicity and cost effectiveness analysis. | Dr. Rudrarpan Chatterjee | Dr. Amita Aggarwal | 2019 | 2022 |
| 8 | Burden of infections in idiopathic inflammatory myopathies. | Dr. Rudrarpan Chatterjee | Dr. Latika Gupta | 2019 | 2022 |
| 9 | Galectin 9: a potential biomarker for lupus nephritis | Dr. Pankti Mehta | Dr. Amita Aggarwal | 2019 | 2020 |
| 10 | MEFV polymorphism as contributor to inflammation amplifier loop in reactive arthritis | Dr. Notin Koshy | Latika Gupta | 2019 | 2020 |
| 11 | Prevalence of Frailty and Its Impact on Quality of Life in Rheumatoid Arthritis | Dr. Sundaram TG | Dr. Able Lawrence | 2018 | 2021 |
| 12 | Factors predicting mortality in an Indian Cohort of Systemic Sclerosis | Dr. Sundaram TG | Dr. Vikas Agarwal | 2018 | 2021 |
| 13 | SCN9a gene polymorphisms in fibromyalgia | Dr. Koshy Nithin Thomas | Dr. Able Lawrence | 2018 | 2021 |
| 14 | MRI and sonography of the knee joint in reactive arthritis | Dr. Koshy Nithin Thomas | Dr. Latika Gupta | 2018 | 2021 |
| 14 | Hip involvement in children with enthesitis related arthritis (ERA) is associated with poor outcomes in adulthood | Dr. Naveen R | Dr. Amita Aggarwal | 2018 | 2021 |
| 15 | Evaluation of clinical and serologic parameters predisposing to subclinical atherosclerosis in ANCA associated vasculitis | Dr. Naveen R | Dr. Durga P Misra | 2018 | 2021 |
| 16 | o develop a composite index using low cost markers in differentiating lupus flare from infection | Dr. Pankti Mehta | Dr. Amita Aggarwal | 2018 | 2021 |
| 17 | To study the T cell and cytokine profile in ankylosing spondylitis with effects of tacrolimus and tadalafil on the cytokines in vitro | Dr. Pankti Mehta | Dr. Vikas Agarwal | 2018 | 2021 |
| 18 | Lymphocyturia and urinary sCD25 (T cell activation marker) as a biomarker for lupus nephritis activity | Dr. Sarit Shekar Pattnaik | Dr. Amita Aggarwal | 2018 | 2019 |
| 19 | Adenosine deaminase level and polymorphism as a predictor of response to MTX in Rheumatoid Arthritis | Dr. G Harikrishnan | Dr. Amita Aggarwal | 2018 | 2019 |
| 20 | Prevalent vertebral fractures incur high risk of future fractures in inflammatory myositis | Dr. Sujata Ganguly | Dr. Latika Gupta | 2017 | 2020 |
| 21 | Urinary C3D is elevated in patients with active lupus nephritis and a fall in its level after 3 months predicts response at 6 months on follow up | Dr. Sujata Ganguly | Dr. Able Lawrence | 2017 | 2020 |
| 22 | Subclinical atherosclerosis in Indian patients with scleroderma- clinical and serological associations | Dr. Harikrishnan G Nair | Dr. Durga P Misra | 2017 | 2020 |
| 23 | Adenosine deaminase gene polymorphism and baseline serum level of ADA as a biomarker of response to methotrexate in rheumatoid arhtirits | Dr. Harikrishnan G Nair | Dr. Amita Aggarwal | 2017 | 2020 |
| 24 | Lymphopenia and urinary sCD25 as a biomarker for lupus nephritis activity | Dr. Sarit Sekhar Pattanaik | Dr. Amita Aggarwal | 2017 | 2020 |
| 25 | An open label study to look at the effect of tacrolimus-tadalafil combination in management of systemic sclerosis ILD | Dr. Sarit Sekhar Pattanaik | Dr. Vikas Agarwal | 2017 | 2020 |
| 26 | Prevalence of cardiovascular risk factors and comparison of risk predicting algorithms in patients with rheumatoid arthritis | Dr. Hafis Muhammed VK | Dr. Vikas Agarwal | 2017 | 2020 |
| 27 | Correlation of pain in osteoarthritis of knee with anatomy of vastus medialis obliquus | Dr. Hafis Muhammed VK | Dr. Able Lawrence | 2017 | 2020 |
| 28 | Evidence of Inflammation amplifier in Enthesitis related arthritis | Dr. Rutviz Mistry | Dr. R.N. Misra | 2016 | 2019 |
| 29 | DRESS : Looks might be deceptive! | Dr. Rutviz Mistry | Dr. Vikas Agarwal | 2016 | 2019 |
| 30 | Subclinical renal disease in rheumatoid arthritis | Dr. Pravin Jain | Dr. Amita Aggarwal | 2016 | 2019 |
| 31 | Potential role on nCD64 as a biomarker to differentiate between bacterial infection and inflammatory disease in a tertiary care hospital | Dr. Pravin Jain | Dr. Vikas Agarwal | 2016 | 2019 |
| 32 | Clinical and radiological study of foot involvement in rheumatoid arthritis | Dr. Sandeep Kansurkar | Dr. Vikas Agarwal | 2016 | 2019 |
| 33 | IL-22 and Th22 cells in peripheral blood and synovial fluid of patients with enthesitis related arthritis category of JIA | Dr. Sandeep Kansurkar | Dr. Amita Aggarwal | 2016 | 2019 |
| 34 | IL-22 and Th22 cells in peripheral blood and synovial fluid of patients with enthesitis related arthritis category of JIA | Dr. Sandeep Kansurkar | Dr. Amita Aggarwal | 2016 | 2019 |
| 35 | Synergy between tuberculin skin test and proliferative T cell responses to PPD or cell-membrane antigens of Mycobacterium tuberculosis for detection of latent TB infection in a high disease-burden setting. | Dr. Suvrat Arya | Dr. R.N. Misra | 2016 | 2019 |
| 36 | Synergy between tuberculin skin test and proliferative T cell responses to PPD or cell-membrane antigens of Mycobacterium tuberculosis for detection of latent TB infection in a high disease-burden setting. | Dr. Suvrat Arya | Dr. R.N. Misra | 2016 | 2019 |
| 37 | Economic impact of Systemic Lupus Erythematosus on patients from India | Dr. Suvrat Arya | Dr. R.N. Misra | 2016 | 2019 |
| 38 | NMR-based Serum Metabolomics of patients with Takayasu arteritis (TA) - Relationship with disease activity | Dr. Avinash Jain | Dr. R.N. Misra | 2015 | 2018 |
| 39 | Distinct T-cell immunophenotypic signature in a subset of sarcoidosis patients with arthritis | Dr. Avinas Jain | Dr. Vikas Agarwal | 2015 | 2018 |
| 40 | Distinct T-cell immunophenotypic signature in a subset of sarcoidosis patients with arthritis | Dr. Abishek A Zanwar | Dr. Amita Aggarwal | 2015 | 2018 |
| 41 | CD39 positive T regulatory cells as marker of Methotrexate response | Dr. Vikas Gupta | Dr. Amita Aggarwal | 2015 | 2018 |
| 42 | Association of TNFAIP3, TNSF4 and ITGAM polymorphysims with SLE in North India | Dr. Vikas Gupta | Dr. R.N. Misra | 2015 | 2018 |
| 43 | Performance of the American College of Rheumatology 2016 criteria for fibromyalgia in a referral care setting | Dr. Sakir Ahmed | Dr. Able Lawrence | 2015 | 2018 |
| 44 | Tadalafil reduces skin fibrosis and profibrotic gene expression in patients with systemic sclerosis | Dr. Sakir Ahmed | Dr. Vikas Agarwal | 2015 | 2018 |
Research Student Project
| S.N. | Title | Name of PI | Funding Agency | Duration | Amount in Rs. |
|---|---|---|---|---|---|
| 1 | Evaluation of cGMP/PKG pathway in pathways in Idiopathic Pulmonary Fibrosis: an in vitro and in vivo study” | Dr. Mohit Kumar Rai (Young Scientist) | ICMR | 2020-2023 | 5103000.00 |
| 2 | Evaluation of D2R pathway for potential anti-viral therapy in Japanese Encephalitis Virus | Dr. Sukanya Tripathy (Young Scientist) | ICMR | 2021-2024 | 3764250.00 |
| 3 | Urinary lymphocyte and monocyte associated proteins (IL-16, CD25, MCP-1 and CD163) as marker of lupus nephritis: derivation of a composite score. | Pratibha Singh (SRF) | ICMR | 2022-2025 | 1320000.00 |
| 4 | Evaluation of P2X7R inflammasome pathway involvement in systemic lupus erythematosus | Abhishek K Singh (SRF) | ICMR | 2022-2025 | 1546800.00 |
| 5 | Evaluation of aortic adventitial fibroblasts in the pathogenesis large vessel vasculitis | Kritika Singh (SRF) | ICMR | 2022-2025 | 1546800.00 |